| Acquirer | Target | Price |
|---|---|---|
| Baxalta Inc. | Collaboration on CAR T cell therapies | $105 million |
| ResMed Inc. | Brightree | $800 million |
| Amgen | Rights to wearable drug injectors | $55 million |
| Recipharm AB | Mitim Srl | $74.7 million |
| McKesson Corporation | 2 oncology companies | $1.2 billion |
Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
